Correlation Between Homologous Recombination Deficiency Status and Resistance to PARP Inhibitors in Chinese Epithelial Ovarian Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Progression-free survival
研究概览
简要总结
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older
- •Pathological confirmation of epithelial ovarian cancer
- •With available tumor tissues
- •Given consents to participate the study
- •With detailed follow-up outcomes
排除标准
- •Not meeting all of the inclusion criteria
- •Declining to accept PARPi as maintenance therapy after the major treatment for cancer
结局指标
主要结局
Progression-free survival
时间窗: One year
Progression-free survival after the start of PARPi
次要结局
- Overall survival(One year)
- Severe adverse events(One year)
研究者
Lei Li
Professor
Peking Union Medical College Hospital